<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00642798</url>
  </required_header>
  <id_info>
    <org_study_id>0431-108</org_study_id>
    <secondary_id>2008_002</secondary_id>
    <nct_id>NCT00642798</nct_id>
  </id_info>
  <brief_title>An Open-Label, Single- &amp; Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects (0431-108)(COMPLETED)</brief_title>
  <official_title>An Open-Label, Single- &amp; Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      To support the registration of sitagliptin 100mg in china.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics of sitagliptin after administration of single and multiple 100-mg doses of sitagliptin to healthy chinese adult subjects.</measure>
    <time_frame>Duration of Trial</time_frame>
  </primary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Diabetes Mellitus Non-insulin-dependent</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sitagliptin phosphate</intervention_name>
    <description>Sitagliptin 100mg once daily on Day 1 for single dose, and once daily on Day4-9 for multiple dose.</description>
    <other_name>Januviaâ„¢</other_name>
    <other_name>MK0431</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject Has Been A Nonsmoker And/Or Has Not Used Nicotine Or Nicotine-Containing&#xD;
             Products For At Least Approximately 6 Months; Subjects Who Have Discontinued Smoking&#xD;
             Or The Use Of Nicotine/Nicotine Containing Products For At Least Approximately 3&#xD;
             Months May Be Enrolled In The Study At The Discretion Of The Investigator&#xD;
&#xD;
          -  Subject Has No Clinically Significant Abnormality On Electrocardiogram (Ecg) Performed&#xD;
             At The Prestudy (Screening) Visit And/Or Prior To Administration Of The Initial Dose&#xD;
             Of Study Drug&#xD;
&#xD;
          -  Subject Is Judged To Be In Good Health Based On Medical History, Physical Examination,&#xD;
             Vital Sign Measurements, And Laboratory Safety Tests Performed At The Prestudy&#xD;
             (Screening) Visit And/Or Prior To Administration Of The Initial Dose Of Study Drug&#xD;
&#xD;
          -  Subject Is Male Or Female 18 To 45 Years Of Age At The Prestudy (Screening) Visit.&#xD;
             Female Subjects Of Reproductive Potential Must Demonstrate A Serum Beta-Hcg Level&#xD;
             Consistent With The Nongravid State At The Prestudy (Screening) Visit And Agree To Use&#xD;
             (And/Or Have Their Partner Use) Two Acceptable Methods Of Birth Control Beginning At&#xD;
             Least 2 Weeks Prior To Administration Of The First Dose Of Study Drug, Throughout The&#xD;
             Study (Including Washout Intervals Between Treatment Periods/Panels) And Until At&#xD;
             Least 2 Weeks After Administration Of The Last Dose Of Study Drug In The Last&#xD;
             Treatment Period. Acceptable Methods Of Birth Control Are: Abstinence, Intrauterine&#xD;
             Device (Iud), Diaphragm, Spermicides, Cervical Cap, Contraceptive Sponge, And Condoms&#xD;
&#xD;
          -  Subject Is Of Chinese Descent With All 4 Biological Grandparents Born In China And Of&#xD;
             Chinese Descent&#xD;
&#xD;
          -  Subject Is Willing To Comply With The Study Restrictions&#xD;
&#xD;
          -  Subject Understands The Study Procedures And Agrees To Participate In The Study By&#xD;
             Giving Written Informed Consent&#xD;
&#xD;
          -  The Subject Has A Body Mass Index (BMI) Between 19 And 24 Kg/M2 And The Body Weight Is&#xD;
             More Than 50 Kg At The Prestudy (Screening) Visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject Consumes Excessive Amounts Of Alcohol, Defined As Greater Than 3 Glasses Of&#xD;
             Alcoholic Beverages (1 Glass Is Approximately Equivalent To: Beer [284 Ml/10&#xD;
             Ounces],Wine [125 Ml/4 Ounces], Or Distilled Spirits [25 Ml/1 Ounce]) Per Day.&#xD;
             Subjects That Consume 4 Glasses Of Alcoholic Beverages Per Day May Be Enrolled At The&#xD;
             Discretion Of The Investigator&#xD;
&#xD;
          -  Subject Consumes Excessive Amounts, Defined As Greater Than 6 Servings (1 Serving Is&#xD;
             Approximately Equivalent To 120 Mg Of Caffeine) Of Coffee, Tea, Cola, Or Other&#xD;
             Caffeinated Beverages Per Day&#xD;
&#xD;
          -  Subject Has A History Of Any Illness That, In The Opinion Of The Study Investigator,&#xD;
             Might Confound The Results Of The Study Or Poses An Additional Risk To The Subject By&#xD;
             Their Participation In The Study&#xD;
&#xD;
          -  Subject Has A History Of Neoplastic Disease.&#xD;
&#xD;
          -  Subject Has A History Of Significant Multiple And/Or Severe Allergies, Or Has Had An&#xD;
             Anaphylactic Reaction Or Significant Intolerability To Prescription Or&#xD;
             Non-Prescription Drugs Or Food&#xD;
&#xD;
          -  Subject Has A History Of Stroke, Chronic Seizures, Or Major Neurological Disorder&#xD;
&#xD;
          -  Subject Has An Estimated Creatinine Clearance Of &lt;=80 Ml/Min Based On The&#xD;
             Cockcroft-Gault Equation&#xD;
&#xD;
          -  Subject Has Had Major Surgery, Donated Or Lost 1 Unit Of Blood (Approximately 500 Ml)&#xD;
             Or Participated In Another Investigational Study Within 4 Weeks Prior To The Prestudy&#xD;
             (Screening) Visit&#xD;
&#xD;
          -  Subject Is A Nursing Mother&#xD;
&#xD;
          -  Subject Is Currently A Regular User (Including Recreational Use)Of Any Illicit Drugs&#xD;
             Or Has A History Of Drug (Including Alcohol) Abuse Within Approximately 6 Months&#xD;
&#xD;
          -  Subject Is Mentally Or Legally Incapacitated, Has Significant Emotional Problems At&#xD;
             The Time Of Prestudy (Screening) Visit Or Expected During The Conduct Of The Study Or&#xD;
             Has A History Of A Clinically Significant Psychiatric Disorder Over The Last 5 To 10&#xD;
             Years.Subjects Who Have Had Situational Depression May Be Enrolled In The Study At The&#xD;
             Discretion Of The Investigator&#xD;
&#xD;
          -  Subject Is Unable To Refrain From Or Anticipates The Use Of Any Medication, Including&#xD;
             Prescription And Non-Prescription Drugs Or Herbal Remedies (Such As St. John&#xD;
             Wort[Hypericum Perforatum]) Beginning Approximately 2 Weeks (Or 5 Half-Lives) Prior To&#xD;
             Administration Of The Initial Dose Of Study Drug, Throughout The Study (Including&#xD;
             Washout Intervals Between Treatment Periods), Until The Post-study Visit&#xD;
&#xD;
          -  Subject Is Under The Age Of Legal Consent&#xD;
&#xD;
          -  There Is Any Concern By The Investigator Regarding The Safe Participation Of The&#xD;
             Subject In The Study Or For Any Other Reason, The Investigator Considers The Subject&#xD;
             Inappropriate For Participation In The Study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>China</country>
  </removed_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>March 7, 2008</study_first_submitted>
  <study_first_submitted_qc>March 21, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2008</study_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

